Assessing the risk of cardiovascular disease in patients with type 2 diabetes

Abstract

Get full access to this article

View all access options for this article.

References

The Audit commission. Testing Times. A Review of Diabetes Services in England and Wales 2001.

National Service Framework for Diabetes: Standards. Department of Health, December 2001.

Mills JD , Grant PJ Insulin resistance, haemostatic factors and cardiovascular risk. Br J Diabetes Vasc Dis 2002;2:19-26.

Parott S. , Godfrey C. , Raw M. , West R. , Mcneill A. Smoking Cessation Guidelines and their Cost-effectiveness. Thorax 1998;53(suppl 5, part 1) S11.

Ukpds Group . Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

Ukpds Group . Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

Ukpds Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998;317:703-13.

Ramsay Le , Williams B. , Johnston GD et al. for the British Hypertension Society. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.

Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.

10.

Parvin HH , Lehnert H. , Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in-patients with type 2 diabetes. N Engl J Med 2000;345:870-8.

11.

MRC / BHF Heart Protection Study. Findings presented at the American Heart Association's Scientific sessions, November 2001.

12.

Rubins HB , Robins SJ , Collins D. et al. for the Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999 :341;410-8.

13.

National Institute for Clinical Excellence. Guidance on the Use of Pioglitazone for type 2 Diabetes Mellitus. Technology Appraisal Guidance No 21, March 2001.

14.

National Institute for Clinical Excellence. Guidance on Rosiglitazone for Type 2 Diabetes Mellitus . Technology Appraisal No 9, August 2000.

15.

National Institute for Clinical Excellence. Inherited Clinical Guideline F. Management of type 2 diabetes: renal disease-prevention and early management, February 2002.

16.

Scottish Intercollegiate Guidelines Network. 55. Management of diabetes. A national clinical guideline, November 2001.

17.

National Institute for Clinical Excellence. Inherited Clinical Guideline E. Management of type 2 diabetes: retinopathy - screening and early management, February 2002 .